Portfolio Management in a Pandemic: A Case Study
The COVID-19 pandemic has brought severe disruption to many industries, including drug development and medical device companies. All businesses face uncertainty about the return to normalcy—and what normal will even look like going forward. For some industries, the new normal might look very different. For others, like pharma and medical devices, the new normal may not require as much change. In fact, some signs of a return to normal are already appearing: Clinical trials are starting to resume. Demand for non-COVID 19 drugs and medical devices is rising again as routine medical care returns. The key uncertainty for these companies is in the timing of return to normal and the rate at which it will happen.
In times like these, when uncertainty is the only sure thing, portfolio management is more important than ever. One pharma company’s story shows how portfolio management can help you plan through the unknowns of the pandemic and continue to manage through it, even as those unknowns evolve. It illustrates how portfolio management can be used to accommodate disruptions, whether internal or external, that impact the company’s ability to deliver. (more…)
